PL4229205T3 - Konstrukty kwasów nukleinowych do transkrypcji VA RNA - Google Patents

Konstrukty kwasów nukleinowych do transkrypcji VA RNA

Info

Publication number
PL4229205T3
PL4229205T3 PL21786513.8T PL21786513T PL4229205T3 PL 4229205 T3 PL4229205 T3 PL 4229205T3 PL 21786513 T PL21786513 T PL 21786513T PL 4229205 T3 PL4229205 T3 PL 4229205T3
Authority
PL
Poland
Prior art keywords
nucleic acid
acid constructs
rna transcription
transcription
rna
Prior art date
Application number
PL21786513.8T
Other languages
English (en)
Inventor
Simon Auslaender
Ulrich Goepfert
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL4229205T3 publication Critical patent/PL4229205T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
PL21786513.8T 2020-10-15 2021-10-13 Konstrukty kwasów nukleinowych do transkrypcji VA RNA PL4229205T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20202010 2020-10-15
PCT/EP2021/078269 WO2022079083A1 (en) 2020-10-15 2021-10-13 Nucleic acid constructs for va rna transcription

Publications (1)

Publication Number Publication Date
PL4229205T3 true PL4229205T3 (pl) 2025-08-18

Family

ID=72964437

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21786513.8T PL4229205T3 (pl) 2020-10-15 2021-10-13 Konstrukty kwasów nukleinowych do transkrypcji VA RNA

Country Status (16)

Country Link
US (2) US12312606B2 (pl)
EP (1) EP4229205B1 (pl)
JP (1) JP2023546116A (pl)
KR (1) KR20230085929A (pl)
CN (1) CN116406425A (pl)
AR (1) AR123777A1 (pl)
AU (1) AU2021360197A1 (pl)
CA (1) CA3197730A1 (pl)
ES (1) ES3035361T3 (pl)
HR (1) HRP20250766T1 (pl)
HU (1) HUE071824T2 (pl)
IL (1) IL302046A (pl)
MX (1) MX2023004052A (pl)
PL (1) PL4229205T3 (pl)
TW (1) TW202223094A (pl)
WO (1) WO2022079083A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4189077A1 (en) 2020-07-30 2023-06-07 Shape Therapeutics Inc. Stable cell lines for inducible production of raav virions
WO2025217034A1 (en) * 2024-04-07 2025-10-16 Spark Therapeutics, Inc. Compositions and methods for the regulation of recombinant adeno-associated virus production

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
ATE157012T1 (de) 1989-11-03 1997-09-15 Univ Vanderbilt Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1994023744A1 (en) 1993-04-16 1994-10-27 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
CN1127527A (zh) 1993-05-17 1996-07-24 加利福尼亚大学董事会 人免疫缺陷型病毒感染和艾滋病的核酶基因治疗方法
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
WO1996026742A1 (en) 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
EP1983057A3 (en) 1995-09-08 2009-01-07 Genzyme Corporation Improved AAV vectors for gene therapy
US6004797A (en) 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
FR2743818B1 (fr) * 1996-01-23 1998-04-10 Agronomique Inst Nat Rech Constructions d'adn et vecteurs d'expression derives du gene de l'arn va i d'adenovirus
US6228646B1 (en) 1996-03-07 2001-05-08 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
EP0912873B1 (de) 1996-07-16 2000-12-06 STEYR MANNLICHER Aktiengesellschaft & Co. KG Gewehr mit lösbarer laufbefestigung
JPH1033175A (ja) 1996-07-24 1998-02-10 Hisamitsu Pharmaceut Co Inc 組換えアデノ随伴ウイルスベクターの製造方法
IL128736A0 (en) 1996-09-06 2000-01-31 Univ Pennsylvania Methods using cre-lox for production of recombinant adeno-associated viruses
DE19650714A1 (de) 1996-12-06 1998-06-10 Melchner Harald Von Prof Dr Genfallen-Konstrukt zur Identifizierung und Isolierung von Genen
US6743620B1 (en) 1996-12-16 2004-06-01 Eisai Co., Ltd. Method for preparing retrovirus vector for gene therapy
CA2269661A1 (en) 1996-12-18 1998-06-25 Targeted Genetics Corporation Recombinase-activatable aav packaging cassettes for use in the production of aav vectors
US6303302B1 (en) 1997-11-19 2001-10-16 The Whitehead Institute For Biomedical Research Regulation of fungal gene expression
AU3097399A (en) 1998-03-20 1999-10-11 Trustees Of The University Of Pennsylvania, The Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
KR20020057975A (ko) 1999-10-29 2002-07-12 오미야 히사시 유전자 도입 방법
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
EP1134287A1 (en) 2000-03-08 2001-09-19 Universite De Geneve A system to control the expression of a given gene using another gene that encodes a polypeptide with recombinant activity
AU2001257611A1 (en) 2000-04-28 2001-11-12 Avigen, Inc. Polynucleotides for use in recombinant adeno-associated virus virion production
CA2416701A1 (en) 2000-07-21 2002-01-31 The United States Of America, As Represented By The Secretary Of Agricul Ture Methods for the replacement, translocation and stacking of dna in eukaryotic genomes
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
AU2002219841A1 (en) 2000-11-16 2002-05-27 Cornell Research Foundation Inc. Vectors for conditional gene inactivation
US7074611B2 (en) 2001-04-27 2006-07-11 Gie-Cerbn, Centre Europeen De Recherche En Biologie Et En Medecine (Gie) Method for the stable inversion of DNA sequence by site-specific recombination and DNA vectors and transgenic cells thereof
DE10210139A1 (de) 2002-03-07 2003-10-23 Medigene Ag Helferkonstrukte für die Herstellung hybrider rAAV-Partikel unterschiedlicher AAV-Serotypen
WO2003084977A1 (en) 2002-04-04 2003-10-16 Xiao Xiao Gene expression control system and its use in recombinant virus packaging cell lines
US7267979B2 (en) 2002-07-01 2007-09-11 Pioneer Hi-Bred International, Inc. Method of controlling gene silencing using site specific recombination
EP1546397A4 (en) 2002-09-27 2007-10-31 Cold Spring Harbor Lab CELL BASED RNA INTERFERENCE AND ASSOCIATED METHODS AND COMPOSITIONS
FR2852021B1 (fr) * 2003-03-04 2007-12-07 Methodes et outils pour le criblage d'arn actifs in cellulo
DE602004030327D1 (de) 2003-05-21 2011-01-13 Genzyme Corp Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
US20050130919A1 (en) 2003-07-18 2005-06-16 University Of Massachusetts Regulatable promoters for synthesis of small hairpin RNA
EP1512742A1 (en) 2003-09-08 2005-03-09 Margarete Odenthal Conditional modification of sirnas expression
WO2005116225A1 (en) 2004-05-25 2005-12-08 Children's Hospital Medical Center Method for introducing and expressing rna in cells
DE602004002471T2 (de) 2004-06-22 2007-01-18 Alcatel Verfahren und System zur Beteitstellung einer Übertragungsverbindung für Datenstromverkehr
US20060110390A1 (en) 2004-08-25 2006-05-25 Myogen, Inc. Inhibition of Ku as a treatment for cardiovascular diseases
US7189561B2 (en) 2004-09-21 2007-03-13 Advec, Inc. Production of adenovirus vectors with reduced levels of replication competent adenovirus contamination
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
AU2006339519A1 (en) 2005-12-16 2007-09-13 The Uab Research Foundation Compositions and methods related to controlled gene expression using viral vectors
US20100173387A1 (en) 2006-04-28 2010-07-08 Universitat Autonoma De Barcelona Method for producing adenovirus vectors for gene therapy and dna sequences used therefor
RS56844B1 (sr) 2007-12-11 2018-04-30 Univ North Carolina Chapel Hill Retrovirusni vektori sa modifikovanim polipurinskim nizom
IL201999A (en) 2009-11-08 2017-10-31 Medical Res & Development Fund For Health Services Bnai Zion Medical Center The State Of Israel A knockout mouse of the 1 – mo gene, a gene associated with morbidly extreme obesity
DK2529020T3 (en) 2010-01-28 2018-08-06 Childrens Hospital Philadelphia SCALABLE PREPARATION PLATF FOR CLEANING VIRAL VECTORS AND CLEANED VIRAL VECTORS FOR USE IN GENTHERAPY
US20130058871A1 (en) 2011-07-28 2013-03-07 Howard Hughes Medical Institute Method and system for mapping synaptic connectivity using light microscopy
ES2857773T5 (es) 2011-08-24 2024-06-04 Univ Leland Stanford Junior Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
AU2013249202B2 (en) 2012-04-18 2018-08-09 The Children's Hospital Of Philadelphia Composition and methods for highly efficient gene transfer using AAV capsid variants
CN104540382A (zh) 2012-06-12 2015-04-22 弗·哈夫曼-拉罗切有限公司 用于产生条件性敲除等位基因的方法和组合物
DK2931897T3 (en) 2012-12-12 2018-02-05 Broad Inst Inc CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS
US10183978B2 (en) 2013-01-27 2019-01-22 Exemplar Genetics, Llc Animal models of duchenne muscular dystrophy
KR20240090694A (ko) 2013-07-22 2024-06-21 더 칠드런스 호스피탈 오브 필라델피아 변종 ａａｖ 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
EP3039129B1 (en) 2013-08-30 2018-06-27 Amgen Inc. High titer recombinant aav vector production in adherent and suspension cells
WO2016057800A1 (en) 2014-10-09 2016-04-14 The Regents Of The University Of California Targeted disruption of a csf1-dap12 pathway member gene for the treatment of neuropathic pain
KR102243243B1 (ko) 2014-10-23 2021-04-22 리제너론 파마슈티칼스 인코포레이티드 신규한 cho 통합 부위 및 이의 용도
AU2016362317B2 (en) 2015-12-01 2023-03-16 Spark Therapeutics, Inc. Scalable methods for producing recombinant Adeno-Associated Viral (AAV) vector in serum-free suspension cell culture system suitable for clinical use
WO2017189683A1 (en) 2016-04-26 2017-11-02 Massachusetts Institute Of Technology Extensible recombinase cascades
WO2018096356A1 (en) 2016-11-28 2018-05-31 Horizon Discovery Limited Methods for conditional gene knock-out
WO2018150271A1 (en) * 2017-02-17 2018-08-23 Lonza Ltd. Mammalian cells for producing adeno-associated viruses
AU2018281306B2 (en) 2017-06-07 2025-04-17 Spark Therapeutics, Inc. Enhancing agents for improved cell transfection and/or rAAV vector production
US20200332278A1 (en) 2017-06-16 2020-10-22 Universite De Strasbourg Methods to generate conditional knock-in models
MY207534A (en) 2017-06-30 2025-03-03 Spark Therapeutics Inc Aav vector column purification methods
EP3456822A1 (en) 2017-09-19 2019-03-20 CEVEC Pharmaceuticals GmbH Inducible aav rep genes
IL275462B2 (en) 2017-12-22 2026-01-01 Genentech Inc Targeted integration of nucleic acids
WO2019217483A1 (en) * 2018-05-07 2019-11-14 Spark Therapeutics, Inc. Plasmid free aav vector producing cell lines
GB201816919D0 (en) 2018-10-17 2018-11-28 Glaxosmithkline Ip Dev Ltd Adeno-associated viral vector producer cell lines
SG11202106217TA (en) * 2018-12-21 2021-07-29 Lonza Walkersville Inc Adeno-associated virus (aav) producer cell line and related methods

Also Published As

Publication number Publication date
KR20230085929A (ko) 2023-06-14
US12312606B2 (en) 2025-05-27
EP4229205C0 (en) 2025-05-14
IL302046A (en) 2023-06-01
TW202223094A (zh) 2022-06-16
WO2022079083A1 (en) 2022-04-21
AR123777A1 (es) 2023-01-11
JP2023546116A (ja) 2023-11-01
HUE071824T2 (hu) 2025-09-28
EP4229205A1 (en) 2023-08-23
CN116406425A (zh) 2023-07-07
US20220135954A1 (en) 2022-05-05
AU2021360197A9 (en) 2023-07-13
US20260103684A1 (en) 2026-04-16
ES3035361T3 (en) 2025-09-02
CA3197730A1 (en) 2022-04-21
EP4229205B1 (en) 2025-05-14
HRP20250766T1 (hr) 2025-08-15
MX2023004052A (es) 2023-05-03
AU2021360197A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
EP3987019A4 (en) Barcode-based nucleic acid sequence assembly
EP3981436A4 (en) Stable target-editing guide rna having chemically modified nucleic acid introduced thereinto
EP3469084A4 (en) HIGHLY SPECIFIC GENOMEDITATION BY CHEMICALLY MODIFIED GUIDE RNAS
IL290274A (en) Methods and reagents for nucleic acid sequencing and associated applications
GB201905651D0 (en) Nucleic acid constructs and methods for their manufacture
EP4376883A4 (en) RNA VACCINES
DK4342987T3 (da) Sammensætning til spaltning af et mål-dna omfattende et guide-rna specifikt for mål-dna'et og cas-protein-kodende nukleinsyre eller cas-protein, og anvendelser deraf
DK3348638T3 (da) Fremgangsmåde til at konvertere genomsekvens fra gram-positiv bakterie ved specifikt at konvertere nukleinsyrebase i tilsigtet dna-sekvens, og molekylkompleks anvendt dertil
EP3775210C0 (en) NUCLEIC ACID MOLECULES FOR PSEUDOURIDYLATION
EP2601293A4 (en) RNA INTERFERENCE-MEDIATED INHIBITION OF CATENINE (CADHERIN-ASSOCIATED PROTEIN) -BEETA-1 (CTNNB1) - GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (SINA)
EP4162044A4 (en) GUIDE RNA TEMPLATE MOLECULES
IL283775A (en) Double-stranded nucleic acid inhibitor molecules containing a triloop
IL291097A (en) Lipidoids for nucleic acid transfection and use thereof
PL4229205T3 (pl) Konstrukty kwasów nukleinowych do transkrypcji VA RNA
BR112012011576A2 (pt) dna de minicírculos superenrolados para aplicações de terapia genética
KR102493424B9 (ko) Rna 검출 방법
EP3773609A4 (en) DOUBLE-STRANDED NUCLEIC ACID INHIBITOR MOLECULES MODIFIED WITH Tm-INCREASING NUCLEOTIDES
EP4257688A4 (en) NUCLEIC ACID CONSTRUCTION FOR AIDS GENE THERAPY
EP4419666A4 (en) METHYLATION ASSAYS OF ENCODED NUCLEIC ACIDS
EP4463553C0 (en) ADVANCED RNA TARGETING (ARNATAR)
EP4208174A4 (en) Nucleic acid-derivatized therapeutics
EP4032551A4 (en) NUCLEIC ACID COMPLEX
EP4382110A4 (en) HAIRPIN NUCLEIC ACID COMPOSITION
EP4144349A4 (en) RNA INTERFERENCE-INDUCING NUCLEIC ACID COMPRISING 8-OXOGUANINE, MODIFIED NUCLEIC ACID BINDING TO MICRORNA COMPRISING 8-OXOGUANINE, AND USES THEREOF
EP4301849A4 (en) MULTIPLEX RNA TARGETING